Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis Save

Date Added
May 20th, 2015
PRO Number
Pro00036914
Researcher
Patricia Griffin
Keywords
Bone, Cancer, Cancer/Brain, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Gynecological, Cancer/Head & Neck, Cancer/Leukemia, Cancer/Lung, Cancer/Lymphoma, Cancer/Myeloma, Cancer/Other, Cancer/Sarcoma, Cancer/Skin, Spinal Cord
Summary

Multiple radiation treatments are frequently used to treat pain caused by cancer that has spread to the spine. Image-guided radiosurgery/stereotactic body radiation therapy (SBRT) is a treatment that uses highly focused x-rays to deliver a single high dose on a specific area of the body. Image-guided radiosurgery/SBRT uses special equipment to position the patient and guide the focused beams toward the area to be treated and away from normal tissue.

The purpose of this part of the study is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

A pilot study evaluating vitamin D deficiency and risk of aggressive uterine cancer in African American as compared to White women Save

Date Added
May 7th, 2015
PRO Number
Pro00030938
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

The purpose of this study is to evaluate vitamin D levels in African American and White women who present with a new diagnosis of uterine cancer.

Institution
MUSC
Recruitment Contact
Tamara Saunders
843-792-6992
saundert@musc.edu

NRG-CC002: PRE-OPERATIVE ASSESSMENT AND POST-OPERATIVE OUTCOMES OF ELDERLY WOMEN WITH GYNECOLOGIC CANCERS Save

Date Added
April 21st, 2015
PRO Number
Pro00043352
Researcher
Jeffrey Elder
Keywords
Aging, Cancer, Cancer/Gynecological, Geriatrics, Surgery, Women's Health
Summary

Participants in this study fall in an older age group and are suspected to have ovarian, fallopian tube, peritoneal or uterine cancer. The usual approach to advanced stage ovarian, fallopian tube, peritoneal or uterine cancer is surgery to remove the cancer and chemotherapy. The surgery could be first in treatment followed by chemotherapy or chemotherapy could be given first to shrink the cancer, possibly followed by surgery and then more chemotherapy. It is sometimes difficult to assess whether a person aged 70 years or older is a good surgical candidate. This study is evaluating a geriatric assessment tool (a questionnaire and some blood work) which would help physicians identify older patients who would do well with surgery. Whether or not patients participate in this study, they will receive treatment and surgery as recommended by thier physician.

Participants will receive the geriatric assessment questionnaire when they are seen by their doctor for consideration of surgery or shortly thereafter. If participants undergo surgery before or after chemotherapy they will be followed for six weeks after surgery to see if they have any complications and what they are. If participants do not have surgery, they will have completed the study once they complete the geriatric assessment questionnaire.

Institution
Greenville
Recruitment Contact
Gina Norris
864-242-2762
gnorris@ghs.org

Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials Save

Date Added
April 7th, 2015
PRO Number
Pro00034158
Researcher
Sharmila Mehta
Keywords
Cancer, Cancer/Brain, Cancer/Breast, Cancer/Gastrointestinal, Cancer/Genitourinary, Cancer/Gynecological, Cancer/Head & Neck, Cancer/Leukemia, Cancer/Lung, Cancer/Lymphoma, Cancer/Myeloma, Cancer/Other, Cancer/Sarcoma, Cancer/Skin, Education, Non-interventional
Summary

The purpose of this study is to find out if providing patients with educational materials helps them to be better prepared for making a decision about participating in a research study to treat their cancer.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

A Phase II Trial Evaluating Cisplatin (NSC#119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva Save

Date Added
February 9th, 2015
PRO Number
Pro00025562
Researcher
David Griffin
Keywords
Cancer, Cancer/Gynecological, Drug Studies
Summary

The purpose of this study is to find out if radiation therapy along with the addition of the drugs, cisplatin and gemcitabine, works in treating locally advanced squamous cell carcinoma of the vulva and to find out what side effects or surgical complications are caused by treatment with this combination.

Institution
Spartanburg
Recruitment Contact
Clinical Research Department
1-800-486-5941
research@srhs.com

RTOG 1203: A RANDOMIZED PHASE III STUDY OF STANDARD VS. IMRT PELVIC RADIATION FOR POST-OPERATIVE TREATMENT OF ENDOMETRIAL AND CERVICAL CANCER (TIME-C) Save

Date Added
January 20th, 2015
PRO Number
Pro00040596
Researcher
David Grisell
Keywords
Cancer/Gynecological, Stage III
Summary

The purpose of this study is to test whether the use of radiation therapy delivery technique called intensity-modulated radiation therapy (IMRT) can reduce the amount and severity of gastrointestinal side effects (such as diarrhea) that result from radiation, compared with standard radiation techniques. In this study patients will get either the IMRT or the standard radiation. Radiation treatment will be delivered daily (Monday through Friday) for 5-6 weeks. Patients may or may not receive weekly cisplatin chemotherapy along with radiation therapy; this will be decided by the treating physician. Following completion of the radiation treatment, patients will be followed for total of 10 years.

Institution
Greenville
Recruitment Contact
Gina Norris
864-242-2762
gnorris@ghs.org

A RANDOMIZED TRIAL OF PELVIC IRRADIATION WITH OR WITHOUT CONCURRENT WEEKLY CISPLATIN IN PATIENTS WITH PELVIC-ONLY RECURRENCE OF CARCINOMA OF THE UTERINE CORPUS Save

Date Added
December 16th, 2014
PRO Number
Pro00039931
Researcher
Jeffrey Elder
Keywords
Cancer, Cancer/Gynecological, Obstetrics and Gynecology, Women's Health
Summary

This is a Phase II study for women diagnosed with pelvic-only and or vaginal recurrence of endometrial cancer following complete hysterectomy and bilateral salpingo-oophorectomy at the time of initial diagnosis . Patients will be randomized to receive external pelvic radiation for approximately 5 weeks followed by brachytherapy OR external pelvic radiation for approximately 5 weeks plus weekly chemotherapy with cisplatin followed by brachytherapy. The study is designed as a screening study to estimate the benefit on progression-free survival of the addition of cisplatin to external pelvic irradiation, overall survival, side effects and evaluate factors at study entry and from original hysterectomy as potential prognostic factors.

Institution
Greenville
Recruitment Contact
Anna Polan
8645222063
apolan@ghs.org

Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Save

Date Added
November 18th, 2014
PRO Number
Pro00039133
Researcher
Jennifer Young
Keywords
Cancer/Gynecological
Summary

This study is for women who have completed treatment (chemotherapy and other treatment) for state II, III, or IV ovarian, fallopian tube or primary peritoneal cancer (cancer having to do with the tissue that lines the inside of the abdomen and covers its organs) and are at risk for the cancer coming back.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu

Using Serum HE4 and CA125 to Monitor the Therapeutic Effects in Ovarian Cancer Patients Based on Histological Subtypes Save

Date Added
August 26th, 2014
PRO Number
Pro00019893
Researcher
Yusheng Zhu
Keywords
Cancer, Cancer/Gynecological
Summary

This study is for female adult subjects with ovarian cancer. CA125 is a protein (compound made by the body) found in blood that is used to monitor treatments and disease progression in ovarian cancer patients. HE4 is also a protein that is used in the evaluation of ovarian cancer and disease monitoring. Both CA125 and HE4 are approved by the FDA to monitor the treatment of ovarian cancers. The purpose of this study is to investigate HE4 and CA125 expressions in different types of ovarian cancer and to evaluate the changes in HE4 and CA125 before and after treatment. A blood draw of approximately 5mL or 1 teaspoon will be taken from eligible subjects before surgery, before each course of chemotherapy and at the time of disease response assessment to evaluate HE4 and CA125 expression.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Save

Date Added
April 30th, 2014
PRO Number
Pro00034096
Researcher
Whitney Graybill
Keywords
Cancer/Gynecological, Women's Health
Summary

This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu

Change_preferences

-- OR --

Create_login